Jodi Braley

904 total citations
11 papers, 339 citations indexed

About

Jodi Braley is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jodi Braley has authored 11 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in Jodi Braley's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (7 papers). Jodi Braley is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Eosinophilic Disorders and Syndromes (7 papers). Jodi Braley collaborates with scholars based in Australia, United States and Netherlands. Jodi Braley's co-authors include Timothy P. Hughes, David M. Ross, Susan Branford, David T Yeung, Haley Altamura, John F. Seymour, Andrew Grigg, Ilaria S. Pagani, Wendy T Parker and Naranie Shanmuganathan and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Environmental Health Perspectives.

In The Last Decade

Jodi Braley

11 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jodi Braley Australia 8 289 240 131 67 40 11 339
Uwe Schwindel Germany 4 279 1.0× 238 1.0× 157 1.2× 32 0.5× 30 0.8× 4 345
Lucy C. Crossman United States 4 283 1.0× 241 1.0× 169 1.3× 35 0.5× 19 0.5× 6 317
Nataliia Glushko Ukraine 2 275 1.0× 217 0.9× 120 0.9× 28 0.4× 77 1.9× 2 327
Jana Linhartová Czechia 7 191 0.7× 120 0.5× 37 0.3× 36 0.5× 45 1.1× 13 242
Adam R. Craig United States 12 380 1.3× 363 1.5× 167 1.3× 37 0.6× 62 1.6× 23 498
Fabian Lang Germany 8 227 0.8× 164 0.7× 69 0.5× 17 0.3× 53 1.3× 39 285
Claudia Venturi Italy 8 175 0.6× 89 0.4× 26 0.2× 27 0.4× 56 1.4× 23 234
Franck E. Nicolini France 3 180 0.6× 160 0.7× 117 0.9× 18 0.3× 15 0.4× 6 190
Rafal Falinski United States 5 386 1.3× 215 0.9× 128 1.0× 11 0.2× 56 1.4× 8 505
Jeffrey Skinner United States 6 188 0.7× 162 0.7× 94 0.7× 10 0.1× 40 1.0× 16 220

Countries citing papers authored by Jodi Braley

Since Specialization
Citations

This map shows the geographic impact of Jodi Braley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jodi Braley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jodi Braley more than expected).

Fields of papers citing papers by Jodi Braley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jodi Braley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jodi Braley. The network helps show where Jodi Braley may publish in the future.

Co-authorship network of co-authors of Jodi Braley

This figure shows the co-authorship network connecting the top 25 collaborators of Jodi Braley. A scholar is included among the top collaborators of Jodi Braley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jodi Braley. Jodi Braley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Pagani, Ilaria S., Naranie Shanmuganathan, Phuong Dang, et al.. (2023). Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy. Blood. 142(25). 2192–2197. 5 indexed citations
2.
Shanmuganathan, Naranie, Ilaria S. Pagani, David M. Ross, et al.. (2020). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 137(9). 1196–1207. 46 indexed citations
3.
Pagani, Ilaria S., Phuong Dang, Verity A Saunders, et al.. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia & lymphoma. 61(10). 2527–2529. 2 indexed citations
4.
Pagani, Ilaria S., Phuong Dang, Verity A Saunders, et al.. (2019). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. 34(4). 1052–1061. 31 indexed citations
5.
Ross, David M., Ilaria S. Pagani, Naranie Shanmuganathan, et al.. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 32(12). 2572–2579. 56 indexed citations
6.
Pagani, Ilaria S., Phuong Dang, Jarrad M. Goyne, et al.. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica. 103(12). 2026–2032. 25 indexed citations
7.
Branford, Susan, David T Yeung, Wendy T Parker, et al.. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 124(4). 511–518. 136 indexed citations
8.
Branford, Susan, David M. Ross, David T Yeung, Jodi Braley, & Timothy P. Hughes. (2014). Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint. Blood. 124(21). 4561–4561. 1 indexed citations
9.
Branford, Susan, David T Yeung, David M. Ross, et al.. (2014). The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment. Blood. 124(21). 816–816. 7 indexed citations
10.
Weisburger, J. H., Jodi Braley, Joel Reinhardt, et al.. (1994). The role of fat and calcium in the production of foci of aberrant crypts in the colon of rats fed 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine.. Environmental Health Perspectives. 102(suppl 6). 53–55. 7 indexed citations
11.
Rivenson, Abraham, Jonathon Reinhardt, César Aliaga, et al.. (1994). Genotoxicity and Carcinogenicity in Rats and Mice of 2-Amino-3, 6- dihydro-3-methyl-7H-imidazolo [4, 5-f]quinolin-7-one: an Intestinal Bacterial an Intestinal Bacterial Metabolite of 2-Amino-3-methyl-3H-imidazo[4, 5-f]quinoline. JNCI Journal of the National Cancer Institute. 86(1). 25–30. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uwe Schwindel Breakdown of academic impact, for papers by Lucy C. Crossman Breakdown of academic impact, for papers by Nataliia Glushko Breakdown of academic impact, for papers by Jana Linhartová Breakdown of academic impact, for papers by Adam R. Craig Breakdown of academic impact, for papers by Fabian Lang Breakdown of academic impact, for papers by Claudia Venturi Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Rafal Falinski Breakdown of academic impact, for papers by Jeffrey Skinner
Rankless by CCL
2026